2 heavy weight drug companies recently locked horns in the Federal Court over one company’s claim that its pain-killer drug gave superior results to the other’s. GlaxoSmithKline Aust took on Reckitt Benckiser Aust over its claim that its Nurofen (active ingredient ibuprofen) gave “faster and more effective relief” from headache pain than did GSKA’s Panadol (active ingredient paracetemol). The Court found that RBA had engaged in misleading/deceptive conduct, due to a lack of sufficient scientific evidence to support its claim. Just one clinical trial had reached the result claimed by GSKA, but 2 later studies failed to replicate it.